Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
203 0 |
SM ISO690:2012 GUGLIELMETTI, Lorenzo, GUNTHER, Gunar, LEU, Claude, CHESOV, Dumitru, NOI, Autori. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. In: European Respiratory Journal, 2022, vol. 59, p. 0. ISSN 0903-1936. DOI: https://doi.org/10.1183/13993003.00388-2022 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Dublin Core Export
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'> <dc:creator>Guglielmetti, L.</dc:creator> <dc:creator>Gunther, G.</dc:creator> <dc:creator>Leu, C.</dc:creator> <dc:creator>Chesov, D.I.</dc:creator> <dc:creator>Noi, A.</dc:creator> <dc:date>2022-05-01</dc:date> <dc:identifier>10.1183/13993003.00388-2022</dc:identifier> <dc:source>European Respiratory Journal () 0-0</dc:source> <dc:subject>MeSH Antibiotics</dc:subject> <dc:subject>Antitubercular</dc:subject> <dc:subject>Antitubercular Agents</dc:subject> <dc:subject>drug therapy</dc:subject> <dc:subject>Combination</dc:subject> <dc:subject>Europe</dc:subject> <dc:subject>Humans</dc:subject> <dc:subject>Rifampin</dc:subject> <dc:subject>Tuberculosis EMTREE drug terms dolutegravir</dc:subject> <dc:subject>isoniazid</dc:subject> <dc:subject>moxifloxacin</dc:subject> <dc:subject>rifapentine</dc:subject> <dc:subject>rifampicin</dc:subject> <dc:subject>rifapentine</dc:subject> <dc:subject>tuberculostatic agent EMTREE medical terms clinical outcome</dc:subject> <dc:subject>disease elimination</dc:subject> <dc:subject>Europe</dc:subject> <dc:subject>European Medicines Agency</dc:subject> <dc:subject>health care access</dc:subject> <dc:subject>health care personnel</dc:subject> <dc:subject>health program</dc:subject> <dc:subject>high income country</dc:subject> <dc:subject>human</dc:subject> <dc:subject>Human immunodeficiency virus infected patient</dc:subject> <dc:subject>Human immunodeficiency virus infection</dc:subject> <dc:subject>Infection control</dc:subject> <dc:subject>latent tuberculosis</dc:subject> <dc:subject>letter</dc:subject> <dc:subject>low income country</dc:subject> <dc:subject>lung tuberculosis</dc:subject> <dc:subject>medication compliance</dc:subject> <dc:subject>middle income country</dc:subject> <dc:subject>patent</dc:subject> <dc:subject>randomized controlled trial (topic)</dc:subject> <dc:subject>treatment duration</dc:subject> <dc:subject>combination drug therapy</dc:subject> <dc:subject>Europe</dc:subject> <dc:subject>tuberculosis</dc:subject> <dc:title>Rifapentine access in Europe: growing concerns over key tuberculosis treatment component</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> </oai_dc:dc>